Therapy of small cell lung cancer with emphasis on oral topotecan

被引：12

作者：

Pirker, Robert ^{[1
]}

Berzinec, Peter ^{[2
]}

Brincat, Stephen ^{[3
]}

Kasan, Peter ^{[4
]}

Ostoros, Gyula ^{[5
]}

Pesek, Milos ^{[6
]}

Plate, Signe ^{[7
]}

Purkalne, Gunta ^{[8
]}

Rooneem, Regina ^{[9
]}

Skrickova, Jana ^{[10
]}

Stanculeanu, Dana ^{[11
]}

Timcheva, Constanta ^{[12
]}

Tzekova, Valentina ^{[13
]}

Zakotnik, Branko ^{[14
]}

Zielinski, Christoph C. ^{[1
]}

Zwitter, Matjaz ^{[15
]}

机构：

[1] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria

[2] Specialised Hosp St Zoerardus Zobor, Dept Oncol, Nitra, Slovakia

[3] Sir Paul Boffa Hosp, Floriana, Malta

[4] Univ Hosp Bratislava, Dept Oncol, Bratislava, Slovakia

[5] Natl Koranyi Inst TB & Pulmonol, Budapest, Hungary

[6] Charles Univ Prague, Fac Med, Plzen, Czech Republic

[7] Riga Easten Univ Hosp, Riga, Latvia

[8] Paul Stradins Clin Univ Hosp Riga, Radiat & Chemotherapy Ctr, Riga, Latvia

[9] N Estonia Reg Hosp, Ctr Canc, Dept Chemotherapy, Tallinn, Estonia

[10] Univ Hosp, Dept Resp Dis & TB, Brno, Czech Republic

[11] Inst Oncol, Bucharest, Romania

[12] Specialized Hosp Active Treatment Oncol, Sofia, Bulgaria

[13] ISUL, Univ Hosp Queen Joanna, Clin Chemotherapy, Sofia, Bulgaria

[14] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia

[15] Inst Oncol Ljubljana, Dept Radiat Oncol, Ljubljana, Slovenia

来源：

LUNG CANCER | 2010年 / 70卷 / 01期

关键词：

Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan; PROPHYLACTIC CRANIAL IRRADIATION; PREVIOUSLY UNTREATED PATIENTS; CISPLATIN PLUS ETOPOSIDE; LONG-TERM SURVIVAL; PHASE-III TRIAL; PROGNOSTIC-FACTORS; THORACIC RADIOTHERAPY; 2ND-LINE TREATMENT; CHEMOTHERAPY; AMRUBICIN;

D O I：

10.1016/j.lungcan.2010.05.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：7 / 13

页数：7

共 50 条

[31] Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer
Pujol, JL
von Pawel, J
Tumolo, S
Martoni, A
Hearn, S
Fields, SZ
Ross, G
ONCOLOGY, 2001, 61 : 47 - 54
[32] Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer
Dabrow, MB
Francesco, MR
Gilman, PB
Cantor, R
Rose, L
Meyer, TJ
CANCER INVESTIGATION, 2003, 21 (04) : 517 - 525
[33] Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
Riemsma, Rob
Simons, Jean P.
Bashir, Zahid
Gooch, Caroline L.
Kleijnen, Jos
BMC CANCER, 2010, 10
[34] Combination chemotherapy with topotecan for non-small cell lung cancer
Dowlati, A
Levitan, N
LUNG CANCER, 2003, 41 : S23 - S26
[35] Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
Rob Riemsma
Jean P Simons
Zahid Bashir
Caroline L Gooch
Jos Kleijnen
BMC Cancer, 10
[36] Topotecan in the first-line treatment of small cell lung cancer
Stewart, DJ
ONCOLOGIST, 2004, 9 : 33 - 42
[37] Evaluation of impact of oral topotecan on health-related quality of life in relapsed small cell lung cancer
Duh, M. S.
Pickard, A. S.
Chen, L.
Antras, L.
Cella, D.
Neary, M. P.
O'Brien, M. E.
VALUE IN HEALTH, 2008, 11 (03) : A26 - A26
[38] A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC)
Kontopodis, E.
Vamvakas, L.
Kalbakis, K.
Vardakis, N. K.
Sfakiotaki, G.
Georgoulias, V.
Agelaki, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[39] Carboplatin plus etoposide or topotecan for small-cell lung cancer
Arrieta, Oscar
Lara-Mejia, Luis
Zatarain-Barron, Zyanya Lucia
LANCET ONCOLOGY, 2020, 21 (09): : 1132 - 1134
[40] Emerging role of weekly topotecan in recurrent small cell lung cancer
Eckardt, JR
ONCOLOGIST, 2004, 9 : 25 - 32

← 1 2 3 4 5 →